E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Immunoglobulin A (IgA) nephropathy |
|
E.1.1.1 | Medical condition in easily understood language |
IgA nephropathy (IgAN) is a kidney disease that occurs when an antibody called immunoglobulin A (IgA) lodges in the filters of the kidneys, causing progressive kidney damage. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10021263 |
E.1.2 | Term | IgA nephropathy |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The efficacy objective of the study is to determine the effect of sparsentan on proteinuria and renal function, in patients newly diagnosed with Immunoglobulin A Nephropathy (IgAN) who are treatment-naive.
The exploratory objective of the study is to determine whether sparsentan has a beneficial effect in patients with IgAN on changes in the kidney tissue by biopsy, quality of life, kidney scarring, cardiac function, blood pressure and other factors measured in the blood.
The safety objective of the study is to assess the safety and tolerability of sparsentan by monitoring of safety endpoints. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patient is willing and able to provide signed informed consent • Patient can understand written and spoken English. • Male and female patients with IgAN aged ≥18 years • Biopsy-proven IgAN, diagnosed within the past 3 months • Urine total protein ≥0.5 g/day and estimated glomerular filtration rate (eGFR) value ≥30 mL/min/1.73 m2 • Not previously treated with ACEI and/or ARB therapy OR not treated with ACEI and/or ARB therapy within the past 12 months • Women of childbearing potential (WOCBP), beginning at menarche, must agree to the use of one highly reliable (ie, can achieve a failure rate of <1% per year) method of contraception from 7 days prior to the first dose of study medication until 90 days after the last dose of study medication. Highly reliable contraception methods include stable oral, implanted, transdermal, or injected contraceptive hormones associated with inhibition of ovulation, or an intrauterine device (IUD) in place for at least 3 months. One additional barrier method must also be used during sexual activity, such as a diaphragm or diaphragm with spermicide (preferred), or male partner’s use of male condom or male condom with spermicide), from Day 1 until 90 days after the last dose of study medication. WOCBP are defined as those who are fertile, following menarche and until becoming postmenopausal unless permanently sterile; permanent sterilisation methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A postmenopausal state is defined as amenorrhoea for more than 24 consecutive months without an alternative medical cause; women on hormone replacement therapy must have a documented plasma follicle-stimulating hormone level ≥40 mIU/mL. All WOCBP must have a negative pregnancy test at Visit 1 (serum) and Visit 2 (urine, with positive results confirmed by serum). |
|
E.4 | Principal exclusion criteria |
• Secondary cause of IgAN • Rapidly progressive glomerulonephritis • History of diabetes mellitus or nonfasting blood glucose >10 mmol/L (180 mg/dL) • Organ transplantation (with the exception of corneal transplants) • Concomitant or recent immunosuppression • History of heart failure (NYHA Class II-IV), clinically significant cerebrovascular disease, or coronary artery disease • Jaundice, hepatitis, or known hepatobiliary disease • Malignancy within the past 2 years • Haematocrit <27%, haemoglobin <90 g/L (9 g/dL), or potassium >5.5 mmol/L (5.5 mEq/L) • History of alcohol or illicit drug use disorder (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) • History of serious side effects or allergic response to any angiotensin II antagonist or endothelin receptor antagonist (ERA) • The female patient is pregnant, plans to become pregnant during the course of the study, or is breastfeeding. • The patient has participated in a study of any investigational product within 28 days prior to screening, or plans to participate in such a study during the course of this study. • The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study, including the ability to swallow the IMP whole. • The patient, in the opinion of the Investigator, has a medical condition or abnormal clinically significant laboratory screening value not listed above that may interfere with the evaluation of sparsentan safety or activity.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the change from baseline in the urine protein/creatinine ratio (UP/C), based on a 24-hour urine sample, at Week 36. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The rate of change in eGFR over a 52-week (approximately 1-year) period following the initial acute effect of therapy (the initial acute effect of therapy is defined as the first 6 weeks of randomised treatment with study medicationÍž thus, the analysis is from 6 weeks post randomisation to 58 weeks post randomisation)
The rate of change in eGFR over a 104-week (approximately 2-year) period following the initial acute effect of therapy (the initial acute effect of therapy is defined as the first 6 weeks of randomised treatment with study medicationÍž thus, the analysis is from 6 weeks post randomisation to 110 weeks post randomisation)
Achievement of urinary protein excretion, based on a 24-hour urine sample, ≤0.3 g/day at Week 36
The mean change from baseline over time in selected proteinuria variables, based on a 24-hour urine sample (eg, total urine protein, total urine albumin, urine albumin/creatinine ratio [UA/C]), up to Week 110
The proportion of patients reaching a confirmed 40% change in eGFR, end-stage renal disease (ESRD), or death. (ESRD is defined as initiation of renal replacement therapy [RRT], kidney transplantation, or sustained eGFR <15 mL/min/1.73m2.)
Proportion of patients with abnormalities in clinical laboratory assessments and vital signs at each visit
Proportion of patients with AEs, serious AEs, AEs leading to discontinuation, AEs leading to death
Mean change from baseline in haematuria at each visit
Change from the diagnostic (baseline) renal biopsy at Week 24, according to the Oxford Classification (MEST-C)
Change from baseline in GFR based on measured GFR (mGFR; 51CR-EDTA method), up to Week 110
Comparison of eGFR and mGFR, up to Week 110
Change from baseline in total body water, as measured by bioimpedance spectroscopy, up to Weeks 110
Mean changes from baseline in quality of life (QOL), measured via patient-reported outcome (PRO) up to Week 110
Change from baseline in the degree of renal interstitial fibrosis, as measured by non-contrast T1 MRI, up to Week 106
Characterisation of sparsentan pharmacokinetic (PK) profile in plasma at Week 12
Change from baseline in biomarkers in plasma, serum, and urine, up to Week 114
Change from baseline in ambulatory blood pressure measurement (ABPM) over 24 hours at Week 6 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Up to Week 114, depending on the end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
When all study samples have been analysed. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 1 |